Abiraterone acetate preferentially enriches for the gut commensal Akkermansia muciniphila in castrate-resistant prostate cancer patients

Daisley, Brendan A.; Chanyi, Ryan M.; Abdur-Rashid, Kamilah; Al, Kait F.; Gibbons, Shaeley; Chmiel, John A.; Wilcox, Hannah; Reid, Gregor; Anderson, Amanda; Dewar, Malcolm; Nair, Shiva M.; Chin, Joseph L.; Burton, Jeremy P.

doi:10.1038/s41467-020-18649-5

Cited by 82 publications

(63 citation statements)

References 62 publications

(79 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From a therapeutic perspective, Akkermansia muciniphila seems to be relevant for the activity of abiraterone acetate in patients with castrate-resistant prostate cancer. This bacterium triggers the bacterial biosynthesis of vitamin K2, which inhibits androgen-dependent tumor growth [ 52 ].…”

Section: Tumor-associated Microbiomementioning

confidence: 99%

Tumor-Associated Microbiome: Where Do We Stand?

Oliva

Mulet-Margalef

Olza

et al. 2021

IJMS

View full text Add to dashboard Cite

The study of the human microbiome in oncology is a growing and rapidly evolving field. In the past few years, there has been an exponential increase in the number of studies investigating associations of microbiome and cancer, from oncogenesis and cancer progression to resistance or sensitivity to specific anticancer therapies. The gut microbiome is now known to play a significant role in antitumor immune responses and in predicting the efficacy of immune-checkpoint inhibitors in cancer patients. Beyond the gut, the tumor-associated microbiome—microbe communities located either in the tumor or within its body compartment—seems to interact with the local microenvironment and the tumor immune contexture, ultimately impacting cancer progression and treatment outcome. However, pre-clinical research focusing on causality and mechanistic pathways as well as proof-of-concept studies are still needed to fully understand the potential clinical utility of microbiome in cancer patients. Moreover, there is a need for the standardization of methodology and the implementation of quality control across microbiome studies to allow for a better interpretation and greater comparability of the results reported between them. This review summarizes the accumulating evidence in the field and discusses the current and upcoming challenges of microbiome studies.

show abstract

Section: Tumor-associated Microbiomementioning

confidence: 99%

Tumor-Associated Microbiome: Where Do We Stand?

Oliva

Mulet-Margalef

Olza

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…lactis LMG P-28149 improved the abundance of A. muciniphila associated with decreased glucose and insulin levels in obese mice (Alard et al 2016). Acetate and lactate derived from the probiotics might stimulate the growth of A. muciniphila because acetate and the acetate-conjugated portion of the drug could boost the growth of A. muciniphila (Daisley et al 2020). In a human study, the administration of L. rhamnosus HN001 and B. longum BB536 increases the abundance of A. muciniphila (Toscano et al 2017).…”

Section: Interaction With Bacteriamentioning

confidence: 99%

The interaction of Akkermansia muciniphila with host-derived substances, bacteria and diets

Hagi

Belzer

2021

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

Trillions of microbes inhabit the human gut and build extremely complex communities. Gut microbes contribute to host metabolisms for better or worse and are widely studied and associated with health and disease. Akkermansia muciniphila is a gut microbiota member, which uses mucin as both carbon and nitrogen sources. Many studies on A. muciniphila have been conducted since this unique bacterium was first described in 2004. A. muciniphila can play an important role in our health because of its beneficial effects, such as improving type II diabetes and obesity and anti-inflammation. A. muciniphila establishes its position as a next-generation probiotic. Besides the effect of A. muciniphila on host health, a technique for boosting has been investigated. In this review, we show what factors can modulate the abundance of A. muciniphila focusing on the interaction with host-derived substances, other bacteria and diets. This review also refers to the possibility of the interaction between medicine and A. muciniphila; this will open up future treatment strategies that can increase A. muciniphila abundance in the gut. Key points • Host-derived substances such as bile, microRNA and melatonin as well as mucin have beneficial effects on A. muciniphila. • Gut and probiotic bacteria and diet ingredients such as carbohydrates and phytochemicals could boost the abundance of A. muciniphila. • Several medicines could affect the growth of A. muciniphila.

show abstract

“…Orally administrated with Enterococcus hirae cause a restoration of CTX anti-tumor efficacy by inducing differentiation of TH17 and pathogenic TH17 cells, promoting tumor-specific Th1 and CTL activity (179). Abiraterone acetate is both an inhibitor of androgen biosynthesis and a highly effective drug of prostate cancer, which reduces the harmful microorganisms and promotes the growth of anticancer microorganisms through metabolizing the gut microbiota (180). Otherwise, Pushalkar et al suggested that bacterial ablation can reshape TME in the orthotopic mouse model of pancreatic cancer (PDAC), induce activation of T cell and increase the sensitivity of immunotherapy (181).…”

Section: Gut Microbiota Affect the Efficacy Of Cancer Immunotherapymentioning

confidence: 99%

Exploring the Emerging Role of the Gut Microbiota and Tumor Microenvironment in Cancer Immunotherapy

Qiu

Lin

et al. 2021

Front. Immunol.

View full text Add to dashboard Cite

The tumor microenvironment (TME) is a complex ecosystem, which includes many different types of cells, abnormal vascular systems, and immunosuppressive cytokines. TME serves an important function in tumor tolerance and escapes from immune surveillance leading to tumor progression. Indeed, there is increasing evidence that gut microbiome is associated with cancer in a variety of ways, as specific microbial signatures are known to promote cancer development and influence safety, tolerability, and efficacy of therapies. Studies over the past five years have shown that the composition of the intestinal microbiota has a significant impact on the efficacy of anticancer immunosurveillance, which contribute to the therapeutic activity of cancer immunotherapies based on targeting cytotoxic T lymphocyte protein 4 (CTLA-4) or programmed cell death protein 1 (PD-1)–programmed cell death 1 ligand 1 (PD-L1) axis. In this review, we mainly discuss the impact of TME on cancer and immunotherapy through immune-related mechanisms. We subsequently discuss the influence of gut microbiota and its metabolites on the host immune system and the formation of TME. In addition, this review also summarizes the latest research on the role of gut microbiota in cancer immunotherapy.

show abstract

Abiraterone acetate preferentially enriches for the gut commensal Akkermansia muciniphila in castrate-resistant prostate cancer patients

Cited by 82 publications

References 62 publications

Tumor-Associated Microbiome: Where Do We Stand?

Tumor-Associated Microbiome: Where Do We Stand?

The interaction of Akkermansia muciniphila with host-derived substances, bacteria and diets

Exploring the Emerging Role of the Gut Microbiota and Tumor Microenvironment in Cancer Immunotherapy

Contact Info

Product

Resources

About